US2020079845A1PendingUtilityA1
Compounds
Est. expiryNov 30, 2026(~0.4 yrs left)· nominal 20-yr term from priority
A61P 9/10A61P 3/10A61P 43/00A61P 7/06A61P 5/14A61P 7/08A61P 37/02A61P 37/06A61P 37/00A61P 3/04A61P 33/00A61P 35/02A61P 27/00A61P 31/12A61P 31/10A61P 35/00A61P 25/00A61P 31/04A61P 29/00A61P 31/16A61P 33/06A61P 31/18A61P 31/00A61P 21/00A61P 19/06A61P 19/02A61P 19/00A61P 17/14A61P 17/06A61P 17/04A61P 17/00A61P 15/00A61P 13/12A61P 11/06A61P 11/00A61P 1/16A61P 1/04A61P 1/00C07K 2317/52C07K 2317/92C07K 16/248C07K 2317/515A61K 2039/505C07K 2317/76G01N 33/6857C07K 2317/567C07K 2317/56C07K 2317/565C07K 2317/51C07K 2317/622C07K 2317/34C07K 2317/73C07K 2317/21G01N 2333/5412C07K 16/24C12N 15/11A61K 39/395
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6.
Claims
exact text as granted — not AI-modified1 . An isolated binding member for human IL-6, which binds human IL-6 with a KD of not more than 30 pM as defined by surface plasmon resonance.
2 .- 73 . (canceled)Join the waitlist — get patent alerts
Track US2020079845A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.